2015运城冠心病诊疗进展_杨伟宪.pptVIP

Title: PLATO研究: Primary Efficacy Endpoint (Composite of 心血管死亡, 心梗, or 卒中) Key Points: 替格瑞洛 significantly reduces the combined risk of 心血管死亡, 心梗, or 卒中 vs 氯吡格雷 in patients with ACS The absolute risk reduction of 替格瑞洛 over 氯吡格雷 starts early and continues to build over the full 1-year treatment regimen 替格瑞洛 provided benefits in the critical early period of risk. Importantly, the benefits were consistent over time The Kaplan-Meier curves continued to diverge up to 12 months, demonstrating a benefit beyond the acute phase Additional Information: In the PLATO研究, 替格瑞洛 significantly decreased the